Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 10,560 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 10,560 shares of the stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $52.68, for a total value of $556,300.80. Following the completion of the transaction, the chief executive officer directly owned 80,360 shares in the company, valued at $4,233,364.80. The trade was a 11.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.52, for a total value of $369,740.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total transaction of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total transaction of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.37, for a total transaction of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.62, for a total value of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total value of $3,005,705.34.

Phibro Animal Health Trading Up 0.3%

NASDAQ:PAHC traded up $0.15 on Thursday, reaching $52.38. The company’s stock had a trading volume of 347,486 shares, compared to its average volume of 255,491. The firm has a market cap of $2.12 billion, a PE ratio of 18.65, a PEG ratio of 0.80 and a beta of 0.74. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The business’s 50-day moving average price is $47.34 and its two-hundred day moving average price is $42.65. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The business had revenue of $373.91 million for the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio is currently 21.33%.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after acquiring an additional 546 shares during the last quarter. Millennium Management LLC grew its stake in Phibro Animal Health by 74.3% in the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after purchasing an additional 154,281 shares in the last quarter. Jane Street Group LLC grew its stake in Phibro Animal Health by 65.3% in the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after purchasing an additional 13,404 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Phibro Animal Health by 97.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock worth $621,000 after purchasing an additional 11,999 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Phibro Animal Health by 0.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 268,877 shares of the company’s stock worth $6,867,000 after purchasing an additional 906 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Wall Street Analysts Forecast Growth

PAHC has been the subject of a number of research analyst reports. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research note on Friday, February 6th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.